Patents by Inventor Michael Lipps
Michael Lipps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082168Abstract: Pharmaceutical formulation dosage form (1) with a core (2) encapsulated by at least one shell (3) and comprising at least one active pharmaceutical ingredient (4), wherein the at least one active pharmaceutical ingredient (4) is embedded in said core (2) of the pharmaceutical formulation dosage form (1), preferably in that said core (2) is formed by a matrix based on xyloglucan (5) containing said active pharmaceutical ingredient (4), and wherein said shell (3) is a pH-responsive coating.Type: ApplicationFiled: November 13, 2023Publication date: March 14, 2024Applicant: Fachhochschule NordwestschweizInventors: Georgios IMANIDIS, Michael LANZ, Georg LIPPS, Valeria PAREDES
-
Patent number: 8739654Abstract: A torque transmitting unit for inclusion in the drive train of a motor vehicle. The unit transmits torque between an engine having an output shaft and a transmission having at least one input shaft that is drivingly coupled with the engine by a clutch and a intermediate torsional vibration damper. The torque transmitting unit includes primary and secondary flywheel masses that are mounted on the transmission input shaft along with the clutch.Type: GrantFiled: April 10, 2008Date of Patent: June 3, 2014Assignee: Schaeffler Technologies GmbH & Co. KGInventors: Peter Himmelreich, Michael Lipps
-
Publication number: 20080282837Abstract: A torque transmitting unit for inclusion in the drive train of a motor vehicle. The unit transmits torque between an engine having an output shaft and a transmission having at least one input shaft that is drivingly coupled with the engine by a clutch and a intermediate torsional vibration damper. The torque transmitting unit includes primary and secondary flywheel masses that are mounted on the transmission input shaft along with the clutch.Type: ApplicationFiled: April 10, 2008Publication date: November 20, 2008Applicant: LuK Lamellen und Kupplungsbau Beteiligungs KGInventors: Peter Himmelreich, Michael Lipps
-
Publication number: 20080039366Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: ApplicationFiled: May 18, 2006Publication date: February 14, 2008Applicant: Advanced Inhalation ResearchInventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Publication number: 20070123449Abstract: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion.Type: ApplicationFiled: October 31, 2006Publication date: May 31, 2007Applicant: Advanced Inhalation Research, Inc.Inventors: Henry Brush, Fen-Ni Fu, Michael Lipp, Jennifer Schmitke
-
Publication number: 20070104657Abstract: This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (?) is greater than 2, optimally greater than 3.Type: ApplicationFiled: December 5, 2006Publication date: May 10, 2007Inventors: Richard Batycky, David Edwards, Michael Lipp
-
Publication number: 20070104658Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: December 12, 2006Publication date: May 10, 2007Inventors: Richard Batycky, Michael Lipp, Ralph Niven
-
Publication number: 20070041912Abstract: The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.Type: ApplicationFiled: September 4, 2003Publication date: February 22, 2007Applicant: ADVANCED INHALATION RESEARCH, INC.Inventors: Elliot Ehrich, Daniel Deaver, Robert Clarke, Michael Lipp
-
Publication number: 20060134009Abstract: The invention relates to a method of treating a corticosteroid-responsive condition of the air passage ways and lungs by delivering a corticosteroid to the pulmonary system of a patient, comprising administering a particle mass comprising a corticosteroid from an inhaler characterized in that the corticosteroid is not substantially deposited in the mouth and throat and is not substantially systemically absorbed. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.Type: ApplicationFiled: December 13, 2005Publication date: June 22, 2006Inventors: Daniel Deaver, Michael Lipp
-
Patent number: 7048908Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: GrantFiled: July 23, 2002Date of Patent: May 23, 2006Assignee: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Publication number: 20060105051Abstract: Methods of making porous particles by using carbon dioxide assisted nebulization (CAN) technology in combination with spray drying technologies are disclosed. As the mixture of carbon dioxide (CO2) and the solvent with drug matrix is expanded through the nebulizer to atmospheric conditions, the resulting aerosol contains fine micro-bubbles and/or micro-droplets that contains dissolved CO2 which is co-currently fed into a spray drying chamber.Type: ApplicationFiled: October 27, 2005Publication date: May 18, 2006Inventors: Blair Jackson, David Bennett, Donghao Chen, Michael Lipp, Purav Dave
-
Publication number: 20050191360Abstract: The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled PTH formulations are disclosed. Improved formulations comprising DPPC, PTH and sodium citrate which are useful in the treatment of lowered PTH conditions are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. Kits containing receptacles of the formulations are also disclosed.Type: ApplicationFiled: February 4, 2005Publication date: September 1, 2005Applicant: Advanced Inhalation Research, Inc.Inventors: Richard Batycky, Michael Lipp
-
Publication number: 20050003003Abstract: Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.Type: ApplicationFiled: April 28, 2003Publication date: January 6, 2005Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit Basu, Giovanni Caponetti, Daniel Deaver, Katharina Elbert, Jeffrey Hrkach, Michael Lipp
-
Publication number: 20030118513Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.Type: ApplicationFiled: July 23, 2002Publication date: June 26, 2003Applicant: Advanced Inhalation Research, Inc.Inventors: Sujit K. Basu, Jeffrey Hrkach, Michael Lipp, Katharina Elbert, David A. Edwards
-
Publication number: 20020150621Abstract: Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diameter of the LPSP ranges from 50 nm to 10 micrometers. The particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of preparing and administering the particles are also provided. Methods of providing a nerve block are also provided by administering LPSPs with a local anesthetic (e.g., bupivacaine) within the vicinity of a nerve.Type: ApplicationFiled: October 16, 2001Publication date: October 17, 2002Inventors: Daniel S. Kohane, Michael Lipp, Robert S. Langer